Onconetix Inc (ONCO)

$0.41 +0.01 (1.42%)
Market Cap 264,000.00
Revenue (ttm) 820,000.00
Net Income (ttm) -14.03M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -1,710.98%
Debt to Equity Ratio 0.00
Volume 519,200
Avg Vol 9,452,748
Day's Range N/A - N/A
Shares Out 656,000.00
Stochastic %K 14%
Beta 3.01
Analysts Strong Buy
Price Target N/A

Company Profile

Onconetix, Inc., a biotechnology company, focuses on the research, development, and commercialization of solutions for men's health and oncology in the United States, the European Union, and Non-European Union. The company offers Proclarix, an in vitro protein-based blood diagnostic test for prostate cancer. It has a license agreement with LabCorp to develop and commercialize Proclarix and other products; and with Immunovia AB for the development, manufacturing, and commercialization of the Panc...

Industry: Biotechnology
Sector: Healthcare
Phone: 513 620 4101
Address:
201 East Fifth Street, Suite 1900, Cincinnati, United States
finansbull88
finansbull88 May. 13 at 8:03 AM
$ONCO Fails-To-Deliver 🚀🚀🚀
0 · Reply
wolfinaofsqueeze
wolfinaofsqueeze May. 13 at 4:51 AM
$ONCO seems like the will present data at AUA 2026 now in may regarding further analysis on Proclarix that is led by LabCorp
0 · Reply
rubiconjay
rubiconjay May. 13 at 4:18 AM
$OBAI $ONCO $AIXI $MEHA $SRXH RubiconJay WATCH OUT List 5/13/2026! May The Stock Gods Be With Us 🙏
0 · Reply
JamilB91
JamilB91 May. 12 at 11:18 PM
$ONCO where can this turd go up to? $1 ?
0 · Reply
rubiconjay
rubiconjay May. 12 at 10:41 PM
$ONCO
0 · Reply
finansbull88
finansbull88 May. 12 at 9:54 PM
$ONCO BOOM is coming Monster Fails-To-Deliver Short squeeze Slapp the ASK and load up now
0 · Reply
streetgambling
streetgambling May. 12 at 9:20 PM
TRADE IDEA: $ONCO. 580K float. 80% short interest. Partnership. Commercial stage product. Trading at .41 a share. Pull the lever. Match the cherries 🍒 🍒 🍒
1 · Reply
streetgambling
streetgambling May. 12 at 8:35 PM
$ONCO market cap has become disconnected from the existence of an actual commercial-stage prostate cancer diagnostic asset. Onconetix isn’t just a shell or preclinical biotech lottery ticket. It owns and has licensed Proclarix, a prostate cancer diagnostic test already approved in Europe and tied to a commercialization agreement with Labcorp for U.S. development and commercialization efforts. Put that in your pipe and smoke it.
1 · Reply
streetgambling
streetgambling May. 12 at 8:23 PM
$ONCO Blue pill says it’s just another garbage penny stock. Red pill says it’s a 580K float with 80% short interest. Do the math.
1 · Reply
finansbull88
finansbull88 May. 12 at 6:14 PM
$ONCO Relax A 1000% run is coming soon.
1 · Reply
Latest News on ONCO
Onconetix files to sell 25M shares of common stock for holders

2026-04-28T20:18:54.000Z - 14 days ago

Onconetix files to sell 25M shares of common stock for holders

Onconetix Highlights Realbotix's Launch of Vinci AI Vision System with Delivery of First Vinci-Equipped Humanoid Robot to Ericsson

Apr 9, 2026, 8:30 AM EDT - 4 weeks ago

Onconetix Highlights Realbotix's Launch of Vinci AI Vision System with Delivery of First Vinci-Equipped Humanoid Robot to Ericsson

Onconetix Highlights Realbotix AI Humanoid Robot Delivery Update

Apr 2, 2026, 8:30 AM EDT - 5 weeks ago

Onconetix Highlights Realbotix AI Humanoid Robot Delivery Update

Onconetix CEO Karina Fedasz to step down, David White to succeed

2026-03-31T13:13:26.000Z - 6 weeks ago

Onconetix CEO Karina Fedasz to step down, David White to succeed

ARTW

Onconetix Appoints David White as Chief Executive Officer and Sammy Dorf as Member of the Board of Directors

Mar 31, 2026, 8:30 AM EDT - 6 weeks ago

Onconetix Appoints David White as Chief Executive Officer and Sammy Dorf as Member of the Board of Directors

Onconetix Highlights Realbotix's Role in Ericsson's World-First 6G Trial Demonstration

Mar 25, 2026, 12:47 PM EDT - 6 weeks ago

Onconetix Highlights Realbotix's Role in Ericsson's World-First 6G Trial Demonstration

Onconetix Inc trading halted, news pending

2026-03-24T23:50:18.000Z - 7 weeks ago

Onconetix Inc trading halted, news pending

Onconetix announces 1-for-5 reverse stock split

2026-03-23T13:12:26.000Z - 7 weeks ago

Onconetix announces 1-for-5 reverse stock split

Onconetix, Inc. Announces 1-for-5 Reverse Stock Split

Mar 23, 2026, 8:30 AM EDT - 7 weeks ago

Onconetix, Inc. Announces 1-for-5 Reverse Stock Split

Onconetix to acquire Realbotix LLC in all-stock transaction

2026-02-12T13:27:43.000Z - 3 months ago

Onconetix to acquire Realbotix LLC in all-stock transaction

Onconetix to Acquire Realbotix LLC, USA-based, AI-Powered Humanoid Robotics Company

Feb 12, 2026, 8:00 AM EST - 3 months ago

Onconetix to Acquire Realbotix LLC, USA-based, AI-Powered Humanoid Robotics Company

Realbotix Corp. Announces the Sale of Realbotix, LLC Subsidiary to a NASDAQ Listed Issuer

Feb 12, 2026, 8:00 AM EST - 3 months ago

Realbotix Corp. Announces the Sale of Realbotix, LLC Subsidiary to a NASDAQ Listed Issuer

Onconetix files to sell 22.07M shares of common stock for holders

2025-11-04T21:45:43.000Z - 6 months ago

Onconetix files to sell 22.07M shares of common stock for holders

Onconetix files to sell 5.1M shares of common stock for holders

2025-10-16T10:10:38.000Z - 7 months ago

Onconetix files to sell 5.1M shares of common stock for holders

Onconetix announces financing through private placement, debt settlement

2025-09-26T12:40:45.000Z - 8 months ago

Onconetix announces financing through private placement, debt settlement

VERU

Onconetix Announces Financing Through a $12.9 Million Private Placement of Series D Preferred Stock and Warrants, Termination of Merger Agreement with Ocuvex, Inc. and Settlement of $8.8 Million Debt with Veru, Inc.

Sep 26, 2025, 8:30 AM EDT - 8 months ago

Onconetix Announces Financing Through a $12.9 Million Private Placement of Series D Preferred Stock and Warrants, Termination of Merger Agreement with Ocuvex, Inc. and Settlement of $8.8 Million Debt with Veru, Inc.

Onconetix, Ocuvex announce mutual termination of merger agreement

2025-09-26T12:20:26.000Z - 8 months ago

Onconetix, Ocuvex announce mutual termination of merger agreement

Joint Press Release: Onconetix and Ocuvex Announce Mutual Termination of Merger Agreement

Sep 26, 2025, 8:15 AM EDT - 8 months ago

Joint Press Release: Onconetix and Ocuvex Announce Mutual Termination of Merger Agreement

Onconetix’s Proteomedix licenses manufacturing IP to Immunovia

2025-09-22T12:10:57.000Z - 8 months ago

Onconetix’s Proteomedix licenses manufacturing IP to Immunovia

Onconetix announces its subsidiary, Proteomedix, licenses manufacturing IP to Immunovia enabling them to independently produce key reagents for their pancreatic cancer test PancreaSureTM

Sep 22, 2025, 8:00 AM EDT - 8 months ago

Onconetix announces its subsidiary, Proteomedix, licenses manufacturing IP to Immunovia enabling them to independently produce key reagents for their pancreatic cancer test PancreaSureTM

Onconetix, Ocuvex execute definitive merger agreement

2025-07-16T12:21:02.000Z - 10 months ago

Onconetix, Ocuvex execute definitive merger agreement

Onconetix and Ocuvex Therapeutics announce execution of definitive merger agreement

Jul 16, 2025, 8:17 AM EDT - 10 months ago

Onconetix and Ocuvex Therapeutics announce execution of definitive merger agreement

Onconetix receives positive decision by Nasdaq Hearings Panel

2025-06-16T12:25:20.000Z - 11 months ago

Onconetix receives positive decision by Nasdaq Hearings Panel

Onconetix, Inc. Announces Positive Decision by Nasdaq Hearings Panel

Jun 16, 2025, 8:22 AM EDT - 11 months ago

Onconetix, Inc. Announces Positive Decision by Nasdaq Hearings Panel

Onconetix Inc trading halted, news pending

2025-06-12T23:50:23.000Z - 11 months ago

Onconetix Inc trading halted, news pending

Onconetix announces 1-for-85 reverse stock split

2025-06-11T15:35:06.000Z - 11 months ago

Onconetix announces 1-for-85 reverse stock split

Onconetix, Inc. Announces 1-for-85 Reverse Stock Split and Results of the Special Meeting of Stockholders

Jun 11, 2025, 11:30 AM EDT - 11 months ago

Onconetix, Inc. Announces 1-for-85 Reverse Stock Split and Results of the Special Meeting of Stockholders

Onconetix receives additional delisting notice from Nasdaq

2025-05-22T21:00:17.000Z - 1 year ago

Onconetix receives additional delisting notice from Nasdaq

Onconetix, Inc. Announces Receipt of Additional Notice from Nasdaq

May 22, 2025, 4:50 PM EDT - 1 year ago

Onconetix, Inc. Announces Receipt of Additional Notice from Nasdaq

Onco-Innovations Uplists to Cboe Canada

May 22, 2025, 10:00 AM EDT - 1 year ago

Onco-Innovations Uplists to Cboe Canada

Biotech Alert: Searches spiking for these stocks today

2025-05-16T15:45:48.000Z - 1 year ago

Biotech Alert: Searches spiking for these stocks today

ADCT ALZN EXEL HUMA INM LEGN OTLK

Onconetix receives additional notice from Nasdaq

2025-04-30T22:20:21.000Z - 1 year ago

Onconetix receives additional notice from Nasdaq

Onconetix signs non-binding LOI for potential combination with Ocuvex

2025-04-08T12:42:04.000Z - 1 year ago

Onconetix signs non-binding LOI for potential combination with Ocuvex

Onconetix Announces Successful Clinical Validation of its Innovative Prostate Cancer Test Proclarix in a Danish cohort

Mar 24, 2025, 8:45 AM EDT - 1 year ago

Onconetix Announces Successful Clinical Validation of its Innovative Prostate Cancer Test Proclarix in a Danish cohort

Onconetix Announces New Clinical Data for its Innovative Prostate Cancer Test Proclarix Accepted for Presentation at 2025 European Association of Urology Congress

Mar 19, 2025, 8:00 AM EDT - 1 year ago

Onconetix Announces New Clinical Data for its Innovative Prostate Cancer Test Proclarix Accepted for Presentation at 2025 European Association of Urology Congress

Onconetix, Inc. Announces Receipt of Notice from Nasdaq Regarding Late Filing of Quarterly Report on Form 10-Q and Subsequent Filing

Dec 12, 2024, 5:00 PM EST - 1 year ago

Onconetix, Inc. Announces Receipt of Notice from Nasdaq Regarding Late Filing of Quarterly Report on Form 10-Q and Subsequent Filing

Virometix appoints Christina Ackermann as Chair and Tim Ramdeen as member of the Board

Oct 8, 2024, 5:00 AM EDT - 1 year ago

Virometix appoints Christina Ackermann as Chair and Tim Ramdeen as member of the Board

OCS VRNA GRDX

Correction: Onconetix Announces Financing Through a $2.0 Million Private Placement of Series C Preferred Stock and Warrants, Establishes a $25 Million Equity Line of Credit

Oct 3, 2024, 4:45 PM EDT - 1 year ago

Correction: Onconetix Announces Financing Through a $2.0 Million Private Placement of Series C Preferred Stock and Warrants, Establishes a $25 Million Equity Line of Credit

Onconetix Announces Financing Through a $2.0 Million Private Placement of Series C Preferred Stock and Warrants, Establishes a $25 Million Equity Line of Credit

Oct 3, 2024, 9:05 AM EDT - 1 year ago

Onconetix Announces Financing Through a $2.0 Million Private Placement of Series C Preferred Stock and Warrants, Establishes a $25 Million Equity Line of Credit

Onconetix, Inc. Announces 1-for-40 Reverse Stock Split and Results of the Annual Meeting of Stockholders

Sep 20, 2024, 11:45 AM EDT - 1 year ago

Onconetix, Inc. Announces 1-for-40 Reverse Stock Split and Results of the Annual Meeting of Stockholders

Onconetix Announces Closing of Warrant Exercise for $1.11 Million Gross Proceeds

Jul 15, 2024, 6:00 AM EDT - 1 year ago

Onconetix Announces Closing of Warrant Exercise for $1.11 Million Gross Proceeds

Onconetix Announces Exercise of Warrants for $1.11 Million Gross Proceeds

Jul 11, 2024, 8:17 AM EDT - 1 year ago

Onconetix Announces Exercise of Warrants for $1.11 Million Gross Proceeds

Onconetix Announces Appointment of Seasoned Biotech Executives Dr. Ajit Singh and Dr. Thomas Meier to Its Board of Directors

Feb 13, 2024, 6:00 AM EST - 2 years ago

Onconetix Announces Appointment of Seasoned Biotech Executives Dr. Ajit Singh and Dr. Thomas Meier to Its Board of Directors

Onconetix™ Chief Executive Officer Dr. Neil J. Campbell Issues Letter to Shareholders

Dec 19, 2023, 7:00 AM EST - 2 years ago

Onconetix™ Chief Executive Officer Dr. Neil J. Campbell Issues Letter to Shareholders

Blue Water Biotech Acquires Proteomedix as Part of Transformation to Commercial Stage Oncology Company; Announces Name Change to Onconetix™

Dec 18, 2023, 7:00 AM EST - 2 years ago

Blue Water Biotech Acquires Proteomedix as Part of Transformation to Commercial Stage Oncology Company; Announces Name Change to Onconetix™

Blue Water Biotech Signs Non-Binding Term Sheet to Acquire a Commercial Stage Oncology Company

Nov 2, 2023, 7:00 AM EDT - 2 years ago

Blue Water Biotech Signs Non-Binding Term Sheet to Acquire a Commercial Stage Oncology Company

Blue Water Biotech Announces It Has Regained Compliance with Nasdaq Listing Rule 5250(c)(1)

Nov 1, 2023, 7:00 AM EDT - 2 years ago

Blue Water Biotech Announces It Has Regained Compliance with Nasdaq Listing Rule 5250(c)(1)

Blue Water Biotech Issues Letter to Shareholders

Oct 30, 2023, 7:00 AM EDT - 2 years ago

Blue Water Biotech Issues Letter to Shareholders

Blue Water Biotech Appoints Dr. Neil J. Campbell as President and CEO and Bruce Harmon as CFO

Oct 10, 2023, 9:00 AM EDT - 2 years ago

Blue Water Biotech Appoints Dr. Neil J. Campbell as President and CEO and Bruce Harmon as CFO

Blue Water Biotech, Inc. Announces Notification From Nasdaq Related to Delayed Quarterly Report on Form 10-Q

Aug 28, 2023, 4:30 PM EDT - 2 years ago

Blue Water Biotech, Inc. Announces Notification From Nasdaq Related to Delayed Quarterly Report on Form 10-Q

Blue Water Biotech Announces Closing of Warrant Exercise and Issuance of New Warrants in A Private Placement For $2.7 Million Gross Proceeds

Aug 3, 2023, 1:02 PM EDT - 3 years ago

Blue Water Biotech Announces Closing of Warrant Exercise and Issuance of New Warrants in A Private Placement For $2.7 Million Gross Proceeds

Blue Water Biotech Announces Exercise of Warrants and Issuance of New Warrants in A Private Placement For $2.7 Million Gross Proceeds

Aug 1, 2023, 8:00 AM EDT - 3 years ago

Blue Water Biotech Announces Exercise of Warrants and Issuance of New Warrants in A Private Placement For $2.7 Million Gross Proceeds

Blue Water Biotech and Knipper Health Join Forces to Distribute Samples for ENTADFI® and ZONTIVITY® to Physicians

Jul 31, 2023, 9:00 AM EDT - 3 years ago

Blue Water Biotech and Knipper Health Join Forces to Distribute Samples for ENTADFI® and ZONTIVITY® to Physicians

Blue Water Biotech Teams with UpScriptHealth to Launch Telemedicine Platform for Benign Prostatic Hyperplasia Asset, ENTADFI®

Jul 25, 2023, 9:00 AM EDT - 3 years ago

Blue Water Biotech Teams with UpScriptHealth to Launch Telemedicine Platform for Benign Prostatic Hyperplasia Asset, ENTADFI®

Blue Water Biotech Issues CEO Shareholder Letter Providing Update on Commercial Launch Activities

Jul 17, 2023, 9:00 AM EDT - 3 years ago

Blue Water Biotech Issues CEO Shareholder Letter Providing Update on Commercial Launch Activities

Blue Water Biotech Teams with Advantage Point Solutions to Provide Healthcare Payer Coverage Support

Jul 11, 2023, 9:00 AM EDT - 3 years ago

Blue Water Biotech Teams with Advantage Point Solutions to Provide Healthcare Payer Coverage Support

Blue Water Biotech Secures License from Ohio State Board of Pharmacy to Operate as Pharmaceutical Wholesaler for its FDA Approved Products

Jul 6, 2023, 5:05 PM EDT - 3 years ago

Blue Water Biotech Secures License from Ohio State Board of Pharmacy to Operate as Pharmaceutical Wholesaler for its FDA Approved Products

Blue Water Biotech Teams with BFW Advertising to Market and Advertise Commercial Product Portfolio

Jul 6, 2023, 7:30 AM EDT - 3 years ago

Blue Water Biotech Teams with BFW Advertising to Market and Advertise Commercial Product Portfolio

Blue Water Biotech Announces Preclinical Data Supporting Immunogenicity of Novel Monkeypox Vaccine Utilizing Norovirus Virus-Like Particle Platform

Jun 28, 2023, 7:55 AM EDT - 3 years ago

Blue Water Biotech Announces Preclinical Data Supporting Immunogenicity of Novel Monkeypox Vaccine Utilizing Norovirus Virus-Like Particle Platform

Blue Water Biotech Collaborates with IQVIA to Build Medical Sales Representative Team to Market Commercial Product Portfolio

Jun 21, 2023, 7:30 AM EDT - 3 years ago

Blue Water Biotech Collaborates with IQVIA to Build Medical Sales Representative Team to Market Commercial Product Portfolio

Blue Water Biotech Expands Commercial Portfolio by Acquiring Six FDA-Approved Drugs Across Various Treatment Areas

Jun 14, 2023, 7:30 AM EDT - 3 years ago

Blue Water Biotech Expands Commercial Portfolio by Acquiring Six FDA-Approved Drugs Across Various Treatment Areas

Blue Water Biotech Reports First Quarter 2023 Financial Results and Recent Business Highlights

May 12, 2023, 6:32 PM EDT - 3 years ago

Blue Water Biotech Reports First Quarter 2023 Financial Results and Recent Business Highlights

Blue Water Biotech to Present Corporate Overview and ENTADFI® Launch Plan at the JMP Securities Life Sciences Conference in New York, NY

May 10, 2023, 12:15 PM EDT - 3 years ago

Blue Water Biotech to Present Corporate Overview and ENTADFI® Launch Plan at the JMP Securities Life Sciences Conference in New York, NY

Blue Water Biotech Appoints Board-Certified Urologist Jay Newmark, M.D., MBA as Chief Medical Officer

Apr 26, 2023, 3:44 PM EDT - 3 years ago

Blue Water Biotech Appoints Board-Certified Urologist Jay Newmark, M.D., MBA as Chief Medical Officer

Blue Water Biotech to Participate in the American Urological Association Annual Meeting 2023 to Promote Benign Prostatic Hyperplasia Treatment ENTADFI®

Apr 25, 2023, 8:00 AM EDT - 3 years ago

Blue Water Biotech to Participate in the American Urological Association Annual Meeting 2023 to Promote Benign Prostatic Hyperplasia Treatment ENTADFI®

Blue Water Vaccines Announces Corporate Name Change to Blue Water Biotech in Connection with Transition into Commercial-Stage Biotechnology Company

Apr 24, 2023, 8:00 AM EDT - 3 years ago

Blue Water Vaccines Announces Corporate Name Change to Blue Water Biotech in Connection with Transition into Commercial-Stage Biotechnology Company

Blue Water Announces Acquisition of ENTADFI®, an FDA-Approved Benign Prostatic Hyperplasia Asset

Apr 20, 2023, 7:30 AM EDT - 3 years ago

Blue Water Announces Acquisition of ENTADFI®, an FDA-Approved Benign Prostatic Hyperplasia Asset

finansbull88
finansbull88 May. 13 at 8:03 AM
$ONCO Fails-To-Deliver 🚀🚀🚀
0 · Reply
wolfinaofsqueeze
wolfinaofsqueeze May. 13 at 4:51 AM
$ONCO seems like the will present data at AUA 2026 now in may regarding further analysis on Proclarix that is led by LabCorp
0 · Reply
rubiconjay
rubiconjay May. 13 at 4:18 AM
$OBAI $ONCO $AIXI $MEHA $SRXH RubiconJay WATCH OUT List 5/13/2026! May The Stock Gods Be With Us 🙏
0 · Reply
JamilB91
JamilB91 May. 12 at 11:18 PM
$ONCO where can this turd go up to? $1 ?
0 · Reply
rubiconjay
rubiconjay May. 12 at 10:41 PM
$ONCO
0 · Reply
finansbull88
finansbull88 May. 12 at 9:54 PM
$ONCO BOOM is coming Monster Fails-To-Deliver Short squeeze Slapp the ASK and load up now
0 · Reply
streetgambling
streetgambling May. 12 at 9:20 PM
TRADE IDEA: $ONCO. 580K float. 80% short interest. Partnership. Commercial stage product. Trading at .41 a share. Pull the lever. Match the cherries 🍒 🍒 🍒
1 · Reply
streetgambling
streetgambling May. 12 at 8:35 PM
$ONCO market cap has become disconnected from the existence of an actual commercial-stage prostate cancer diagnostic asset. Onconetix isn’t just a shell or preclinical biotech lottery ticket. It owns and has licensed Proclarix, a prostate cancer diagnostic test already approved in Europe and tied to a commercialization agreement with Labcorp for U.S. development and commercialization efforts. Put that in your pipe and smoke it.
1 · Reply
streetgambling
streetgambling May. 12 at 8:23 PM
$ONCO Blue pill says it’s just another garbage penny stock. Red pill says it’s a 580K float with 80% short interest. Do the math.
1 · Reply
finansbull88
finansbull88 May. 12 at 6:14 PM
$ONCO Relax A 1000% run is coming soon.
1 · Reply
drweinerdog1
drweinerdog1 May. 12 at 4:02 PM
$ONCO oh yes stupid me buying more shares at .40 trying to keep my average to break even at a 100 percent run
0 · Reply
Siara1620
Siara1620 May. 12 at 3:52 PM
$ONCO Meanwhile, POS
0 · Reply
finansbull88
finansbull88 May. 12 at 2:26 PM
$ONCO This is a ticking atomic bomb that can go off at any time Share with anyone who wants to make a lot of money
0 · Reply
Siara1620
Siara1620 May. 12 at 2:20 PM
$ONCO We'll see
1 · Reply
Bikinibullshark
Bikinibullshark May. 12 at 2:18 PM
$ONCO back to green. Let’s go!
0 · Reply
finansbull88
finansbull88 May. 12 at 2:11 PM
$ONCO Smart short squeeze guarantee
0 · Reply
finansbull88
finansbull88 May. 12 at 1:05 PM
$ONCO Monster Fails-To-Deliver and short squeeze is coming Load up and Hold for GOLD now.
2 · Reply
Siara1620
Siara1620 May. 12 at 1:01 PM
$ONCO I added a few pieces yesterday. We'll see what happens.
0 · Reply
WannabeTrad3r
WannabeTrad3r May. 12 at 12:55 PM
$ONCO adding some
0 · Reply
Bank_of_Gotham
Bank_of_Gotham May. 12 at 12:55 PM
$ONCO Cheap down here.I´m adding
1 · Reply
finansbull88
finansbull88 May. 12 at 12:36 PM
$ONCO loading zone !!!!
0 · Reply
finansbull88
finansbull88 May. 12 at 9:40 AM
$ONCO Follow the SEC filings BECAUSE THIS STOCK WILL EXPLODE UP- AMAZING news coming SOON. https://finance.yahoo.com/sectors/technology/articles/onconetix-highlights-realbotix-ai-humanoid-123000246.html $ONCO There are now 15 -20++++ million shares that are Fails-To-Deliver (has never been higher). I remember when this happened in GameStop $GME and AMC Entertainment $AMC Now is a great buying opportunity before BIG news comes this week. CTB almost 600% and float is locked = Short squeeze is guaranteed to come on volume.
0 · Reply